Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

119 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Trends in Grade 5 Toxicity and Response in Phase I Trials in Hematologic Malignancy: 20-Year Experience From the Cancer Therapy Evaluation Program at the National Cancer Institute.
Chihara D, Huang EP, Finnigan SR, Cordes LM, Skorupan N, Fukuda Y, Rubinstein LV, Ivy SP, Doroshow JH, Nastoupil LJ, Flowers CR, Takebe N. Chihara D, et al. Among authors: huang ep. J Clin Oncol. 2022 Jun 10;40(17):1949-1957. doi: 10.1200/JCO.21.02190. Epub 2022 Mar 9. J Clin Oncol. 2022. PMID: 35263120 Free PMC article. Clinical Trial.
Design of phase I combination trials: recommendations of the Clinical Trial Design Task Force of the NCI Investigational Drug Steering Committee.
Paller CJ, Bradbury PA, Ivy SP, Seymour L, LoRusso PM, Baker L, Rubinstein L, Huang E, Collyar D, Groshen S, Reeves S, Ellis LM, Sargent DJ, Rosner GL, LeBlanc ML, Ratain MJ. Paller CJ, et al. Clin Cancer Res. 2014 Aug 15;20(16):4210-7. doi: 10.1158/1078-0432.CCR-14-0521. Clin Cancer Res. 2014. PMID: 25125258 Free PMC article. Review.
RECIST 1.1 for Response Evaluation Apply Not Only to Chemotherapy-Treated Patients But Also to Targeted Cancer Agents: A Pooled Database Analysis.
Litière S, Isaac G, De Vries EGE, Bogaerts J, Chen A, Dancey J, Ford R, Gwyther S, Hoekstra O, Huang E, Lin N, Liu Y, Mandrekar S, Schwartz LH, Shankar L, Therasse P, Seymour L; RECIST Working Group. Litière S, et al. J Clin Oncol. 2019 May 1;37(13):1102-1110. doi: 10.1200/JCO.18.01100. Epub 2019 Mar 12. J Clin Oncol. 2019. PMID: 30860949 Free PMC article.
Factors Affecting Combination Trial Success (FACTS): Investigator Survey Results on Early-Phase Combination Trials.
Paller CJ, Huang EP, Luechtefeld T, Massett HA, Williams CC, Zhao J, Gravell AE, Tamashiro T, Reeves SA, Rosner GL, Carducci MA, Rubinstein L, Ivy SP. Paller CJ, et al. Among authors: huang ep. Front Med (Lausanne). 2019 Jun 4;6:122. doi: 10.3389/fmed.2019.00122. eCollection 2019. Front Med (Lausanne). 2019. PMID: 31214592 Free PMC article.
Criteria for the translation of radiomics into clinically useful tests.
Huang EP, O'Connor JPB, McShane LM, Giger ML, Lambin P, Kinahan PE, Siegel EL, Shankar LK. Huang EP, et al. Nat Rev Clin Oncol. 2023 Feb;20(2):69-82. doi: 10.1038/s41571-022-00707-0. Epub 2022 Nov 28. Nat Rev Clin Oncol. 2023. PMID: 36443594 Free PMC article. Review.
119 results